Uncommon efforts for an uncommon tumor: the case for development of newer systemic therapies for advanced thymic epithelial tumors

Affiliations

Comment

Mohammed Amine Achhal El Kadmiri et al. Mediastinum. 2018 Mar.

. 2018 Mar:2:12.

doi: 10.21037/med.2018.03.04. Epub 2018 Mar 13.

¹ Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Novel Agents in the Treatment of Thymic Malignancies.
Merveilleux du Vignaux C, Maury JM, Girard N. Merveilleux du Vignaux C, et al. Curr Treat Options Oncol. 2017 Aug 10;18(9):52. doi: 10.1007/s11864-017-0495-8. Curr Treat Options Oncol. 2017. PMID: 28795288 Review.

1. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003;76:878–84; discussion 84–5. - PubMed
1. Girard N, Ruffini E, Marx A, et al. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5:v40–55. - PubMed
1. Kelly RJ, Petrini I, Rajan A, et al. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011;29:4820–7. - PMC - PubMed
1. Rajan A, Giaccone G. Chemotherapy for thymic tumors: induction, consolidation, palliation. Thorac Surg Clin 2011;21:107–14, viii. - PubMed
1. Scorsetti M, Leo F, Trama A, et al. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol 2016;99:332–50. - PubMed